A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2023; you can also visit the original URL.
The file type is application/pdf
.
Editorial on HIT series on emergent CAR T-cell toxicities
2023
Conflict of interest: COI declared -see note COI notes: H.E.H. has equity in Allovir and Marker Therapeutics and share options in Fresh Wind Biotherapeutics and Coregen, has served on advisory boards for Tessa Therapeutics and GSK and received research support from Athenex and Tessa Therapeutics.
doi:10.1182/blood.2023020228
pmid:36928098
fatcat:54fozejkxvg77gtl2ggss56dwi